关于使用部分闲置募集资金暂时补充流动资金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，公告不存 在虚假记载、误导性陈述或重大遗漏。 杭州百诚医药科技股份有限公司（以下简称"公司"）于 2025 年 12 月 19 日召开第四届董事会第七次会议，审议通过了《关于使用部分闲置募集资金暂时 补充流动资金的议案》，同意公司在不影响募集资金项目建设的情况下，使用不 超过人民币 13,970 万元的闲置募集资金暂时补充流动资金，使用期限为自董事 会审议通过之日起不超过 12 个月，到期之前归还至募集资金专户。同时，董事 会同意对暂时补充流动资金的使用新增设立募集资金专项账户，用于公司闲置募 集资金暂时补充流动资金的存放和使用，并同意公司与相关方签订《募集资金三 方监管协议》。现将有关情况公告如下： 一、募集资金的情况 证券代码：301096 证券简称：百诚医药 公告编号：2025-071 杭州百诚医药科技股份有限公司 截至2025年9月30日，公司首次公开发行股份募集资金使用情况如下： 单位：万元 | | 投资总额 | 募集资金承诺 | 截至 | 2025 年 9 | | --- | --- | -- ...

国金证券股份有限公司 关于杭州百诚医药科技股份有限公司 截至 2025 年 9 月 30 日，公司首次公开发行股份募集资金使用情况如下：单 位：万元 | 募集资金投资项目 | 投资总额 | 募集资金承诺投 | 截至 | 2025 年 9 | 月 | 30 | 日 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 资金额 | | 使用情况 | | | | | 杭州百诚医药科技股份有限公司 总部及研发中心项目 | 65,051.78 | 65,051.78 | | | 66,246.27 | | | | 总计 | 65,051.78 | 65,051.78 | | | 66,246.27 | | | 三、历次使用部分闲置募集资金暂时补充流动资金的情况 2022 年 1 月 4 日，公司召开第二届董事会第二十一次会议和第二届监事会 第七次会议，审议通过了《关于使用部分闲置募集资金暂时补充流动资金的议案》， 同意公司在不影响募集资金项目建设的情况下，使用不超过人民币 50,000 万元 的闲置募集资金暂时补充流动资金，使用期限为自董事会审议通过之日起不 ...

中国经济网北京12月15日讯 百诚医药(301096.SZ)昨晚披露关于员工战略配售资管计划减持股份预 披露公告称，持有公司股份1,130,653股（占公司总股本的1.0425%，总股本已剔除回购专户股份数 777,300股，下同）的股东富诚海富资管－杭州银行－富诚海富通百诚医药员工参与创业板战略配售集 合资产管理计划（以下简称"员工战略配售资管计划"）拟在公告披露之日起15个交易日后的3个月内以 大宗交易方式或集中竞价交易方式减持公司股份不超过550,628股（占公司总股本的0.5077%）。 本次拟通过员工战略配售资管计划减持的份额持有人为公司原董事、高级管理人员刘一凡及公司原 高级管理人员陈晓萍。刘一凡持有员工战略配售资管计划份额2,205万元（占资管计划份额比例 24.50%），即间接持有公司277,010股（占公司总股本0.2554%）；陈晓萍持有员工战略配售资管计划份 额2,178万元（占资管计划份额比例24.20%），即间接持有公司273,618股（占公司总股本0.2523%）。 上述人员已于2025年2月7日因任期届满离任上述职务，截至公告披露日，离任时间已满六个月。 上市首日，百诚医药创下股 ...

Group 1 - Anbotong plans to issue H-shares and list on the Hong Kong Stock Exchange, with the board authorizing management to start preparations within 12 months [1] - Xiangsheng Medical proposes a cash dividend of 3 yuan per 10 shares for the first three quarters of 2025 [2] - Junshi Biosciences receives FDA approval for clinical trials of JS212, a dual-specific antibody-drug conjugate for treating advanced solid tumors [3] Group 2 - Zhonghuan Environmental plans to raise up to 300 million yuan by issuing shares to a specific entity, with funds allocated for working capital and bank loan repayment [4] - Guao Technology announces a change in actual control to Xu Yinghui, with stock resuming trading on December 15 [5] - Jiaze New Energy intends to invest approximately 3.557 billion yuan in a green hydrogen and methanol project in Heilongjiang [6] Group 3 - Shanghai Airport reports a 15.47% year-on-year increase in passenger throughput at Pudong International Airport for November [7] - Innovent Biologics achieves primary endpoint in a Phase IIb study of Obinutuzumab for systemic lupus erythematosus, with plans for a Phase III trial [8] - Saiyi Information leads a national major science and technology project on intelligent manufacturing systems and robotics [9] Group 4 - Yipin Hong's Qinxing Qingjie oral solution is approved as a national second-level protected traditional Chinese medicine [10] - Yipin Hong's stake in US-based Arthrosi Therapeutics is set to be acquired by Sobi for a total of up to 950 million USD [11] - Pudong Jinqiao announces the resignation of Chairman Wang Ying due to job transfer [12] Group 5 - Jiaze New Energy plans to invest in two wind power projects with a total estimated investment of approximately 2.366 billion yuan [13] - Jinpan Technology receives approval from the CSRC for issuing convertible bonds to unspecified investors [14] - Zoli Pharmaceutical intends to acquire a multi-trace element injection asset group for 356 million yuan [15] Group 6 - Jiuan Medical's US subsidiary receives pre-market notification from the FDA for multiple testing products [16][17] - Changfei Optical Fiber's subsidiary plans to participate in establishing an investment fund with a total subscription amount of 830 million yuan [18] - Chenfeng Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [19][20][21][22]

12月14日，截至20时，上市公司发布的股份减持公告汇总如下： 晨丰科技（603685）股东杭州宏沃计划在2026年1月7日至4月6日期间，通过集中竞价和大宗交易方式合 计减持不超过752万股，约占公司总股本的3%。 新雷能（300593）董事、副总经理刘志宇因资金需求，计划自2026年1月7日至2026年4月6日期间通过集 中竞价和大宗交易方式减持不超过40万股公司股份，占剔除回购专用账户后的总股本的0.07%。 凯普生物（300639）职工代表董事谢龙旭因个人资金需求，计划在2026年1月7日至2026年4月6日期间， 通过集中竞价方式减持不超过9.39万股公司股份，约占公司总股本的0.0150%。 百诚医药（301096）股东富诚海富资管—杭州银行—富诚海富通百诚医药员工参与创业板战略配售资管 计划，计划在未来三个月内通过大宗交易或集中竞价方式减持不超过55万股，约占公司总股本的 0.5077%。 万丰股份（603172）股东舟山瑞好通过大宗交易方式减持公司股份233万股，占公司总股本的1.75%。 圣诺生物（688117）股东川发投资通过集中竞价及大宗交易方式累计减持公司股份403万股，占公司总 股本 ...

Corporate Changes - Wang Ying, the chairman of Pudong Jinqiao, has resigned due to work transfer [2] - Xu Yinghui has become the new actual controller of Gu Ao Technology after a voting rights entrustment agreement [4][5] Profit Distribution - Xiangsheng Medical plans to distribute a cash dividend of 3 yuan per 10 shares for the first three quarters of 2025 [3] Investment Projects - Jiaze New Energy intends to invest approximately 3.557 billion yuan in a green hydrogen and methanol co-production project in Jixi City, Heilongjiang Province [6] - Longfei Optical Fiber's subsidiary plans to participate in establishing an investment fund with a total subscription amount of 830 million yuan [11] Financing Activities - Jinpan Technology has received approval from the China Securities Regulatory Commission to issue convertible bonds to unspecified investors [7] Acquisitions - Zoli Pharmaceutical has signed an agreement to acquire a multi-trace element injection asset group from Future Medicine for a total price of 356 million yuan [8] Product Approvals - Nine安 Medical's U.S. subsidiary has received pre-market notifications from the FDA for its multi-detection kits for various viruses [9] National Projects - Saiyi Information has been approved to lead a national major science and technology project focused on intelligent manufacturing systems and robotics [10]

Group 1 - Pudong Jinqiao's chairman Wang Ying has resigned due to job transfer, ceasing to hold positions as director, chairman, and committee member [2] - Xiangsheng Medical plans to distribute a cash dividend of 3 yuan per 10 shares to all shareholders based on the total share capital [3] - Gu Ao Technology's actual controller has changed to Xu Yinghui, with stock resuming trading on December 15 [4] Group 2 - Jiaze New Energy plans to invest approximately 3.557 billion yuan in a green hydrogen and aviation fuel chemical co-production project in Jixi City [5] - Jinpan Technology has received approval from the China Securities Regulatory Commission to issue convertible bonds to unspecified investors [6] - Zoli Pharmaceutical intends to acquire a multi-trace element injection asset group for a total price of 356 million yuan [7] Group 3 - Jiuan Medical's U.S. subsidiary has received pre-market notifications from the FDA for four and three-in-one testing products [8] - Saiyi Information has been approved for a national major science and technology project focusing on intelligent manufacturing systems and robotics [9] - Changfei Fiber's subsidiary plans to participate in establishing an investment fund with a total subscription amount of 830 million yuan [10] Group 4 - Chengfeng Technology's shareholder, Hangzhou Hongwo, plans to reduce its stake by up to 3% of the company's shares [12] - Minxin Co., Ltd.'s deputy general manager plans to reduce holdings by up to 220,000 shares, representing 0.3925% of the total share capital [13] - Xinle Energy's director plans to reduce holdings by up to 400,000 shares, accounting for 0.07% of the total share capital [14]

智通财经APP讯，百诚医药(301096.SZ)公告，公司股东富诚海富资管-杭州银行-富诚海富通百诚医药员 工参与创业板战略配售集合资产管理计划(简称"员工战略配售资管计划")拟在本公告披露之日起15个交 易日后的3个月内以大宗交易方式或集中竞价交易方式减持本公司股份不超过55.06万股(占公司总股本 的0.5077%)。 ...

百诚医药（301096）(301096.SZ)公告，公司股东富诚海富资管-杭州银行（600926）-富诚海富通百诚医 药员工参与创业板战略配售集合资产管理计划(简称"员工战略配售资管计划")拟在本公告披露之日起15 个交易日后的3个月内以大宗交易方式或集中竞价交易方式减持本公司股份不超过55.06万股(占公司总 股本的0.5077%)。 ...

Group 1 - The core point of the news is that Baicheng Pharmaceutical announced a plan for shareholders to reduce their holdings in the company through block trading or centralized bidding within three months after the announcement [1] - The shareholder involved in the reduction is a management asset management plan, which includes former directors and senior management members, indicating potential changes in insider ownership [1] - The total number of shares to be reduced is approximately 550,000, representing 0.5077% of the company's total share capital [1] Group 2 - For the first half of 2025, Baicheng Pharmaceutical's revenue composition shows that the CRO business accounts for 86.22%, commercial production for 10.28%, and CDMO business for 3.5% [2] - The current market capitalization of Baicheng Pharmaceutical is 5.9 billion yuan [3]